Multi-arming ourselves against drug-resistant bacteria

Jessia Raherisoanjato; Matthew T Henke

doi:10.1016/j.chom.2023.06.011

Multi-arming ourselves against drug-resistant bacteria

Cell Host Microbe. 2023 Jul 12;31(7):1075-1076. doi: 10.1016/j.chom.2023.06.011.

Authors

Jessia Raherisoanjato¹, Matthew T Henke²

Affiliations

¹ Department of Pharmaceutical Sciences and Center for Biomolecular Sciences, College of Pharmacy University of Illinois Chicago, Chicago, IL 60607, USA.
² Department of Pharmaceutical Sciences and Center for Biomolecular Sciences, College of Pharmacy University of Illinois Chicago, Chicago, IL 60607, USA. Electronic address: mhenke3@uic.edu.

PMID: 37442092
DOI: 10.1016/j.chom.2023.06.011

Abstract

New classes of antibiotics are desperately needed in our fight against antibiotic-resistant bacterial infections. Jia et al. publish a new "multi-armed" antibiotic scaffold that effectively treats methicillin-resistant Staphylococcus aureus infections in mice. These compounds are structurally unlike pre-clinical or approved antibiotics, and they may hit an "irresistible" target.

MeSH terms

Animals
Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Methicillin-Resistant Staphylococcus aureus*
Mice
Microbial Sensitivity Tests
Staphylococcal Infections* / drug therapy
Staphylococcal Infections* / microbiology

Substances

Anti-Bacterial Agents